Background Tofacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of
rheumatoid arthritis. We assessed the efficacy and safety of tofacitinib after methotrexate …

Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor
for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-…

Objective To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid
arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of …

Introduction This study explored patients’ and dermatologists’ priority outcomes for treatment
to address, clinical outcome assessments (COA) for use in vitiligo clinical trials, and …

Background This study sought to evaluate the efficacy and safety of tofacitinib in patients with
rheumatoid arthritis with distinct treatment histories. Methods Pooled phase II/III trial data …

Objective Tofacitinib is an oral Janus kinase inhibitor for treatment of RA. We compared
tofacitinib modified-release (MR) 11 mg once daily (QD) with tofacitinib immediate-release (IR) 5 …

Objectives To report the efficacy, safety and patient-reported outcome measures (PROs) of
tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid …

Disodium ascorbyl phytostanyl phosphate (FM-VP4) consists of ascorbic acid covalently
bound to phytostanols by a phosphodiester linkage and is derived as the disodium salt. The …

Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). To provide additional clinical evidence in regulatory submissions for a modified-…

The cholesterol-lowering and anti-atherogenic effects of non-hydrogenated (FCP-3P1
containing 69% β-sitosterol, 16% sitostanol, and 13% campesterol) and hydrogenated (FCP-3P2 …